Shots could start early next month – perfectly safe at Christmas with the first babies – if regulators move forward.
You have successfully cast your vote
Details of Pfizer’s research posted online on Friday. Food and Drug Administration advisers will publicly debate the evidence next week. The FDA is expected to review the company’s safety and performance data next Friday. If the FDA finally approves the shots, the Centers for Disease Control and Prevention will make the final decision on who should receive them in early November.
Full-powered Pfizer shots are already approved for ages 12 or older, but pediatricians and many parents are anxious to help young children prevent the growing infection from the extra-contagious Delta variant and help keep children in school.
More than 25,000 pediatricians and primary care providers have already signed up to get the shots into the little arms.
The Biden administration has purchased adequate baby-sized doses বিশেষ in special orange-covered vials to differentiate them from adult vaccines জন্য for a total of 28 million 5- to 11-year-olds in the country. If the vaccine is cleared, millions of doses will be immediately sent across the country, including baby-sized needles.
A Pfizer study tracked 2,28 children of that age who received two shots without a placebo or low-dose vaccine at three-week intervals. Each dose was one-third of the amount given to adolescents and adults.
The researchers calculated that the low-dose vaccine was about 91% effective, based on 16 Covid-19 cases where young people were given dummy shots, three of the vaccinated children. No serious illness was reported in any of the young people, but vaccinated people had much milder symptoms than their unvaccinated counterparts.
Also, young children given low-dose shots produce stronger coronavirus-resistant antibody levels than adolescents and regular adults.
This is important data considering that the hospitalization of most vaccinated children reached record levels last month.
The CDC reported earlier this week that despite the increase in delta mutants between June and September, the Pfizer vaccine was 93% effective in preventing hospitalization among 12- to 18-year-olds.
Pfizer’s study of young children has shown that low-dose shots have proven safe, with similar or less temporary side effects such as feeling pain in the arm, fever or adolescent pain.
The study is not too large to detect any extremely rare side effects, such as inflammation of the heart that sometimes occurs after the second dose, in most young people.
According to the CDC, while children have a lower risk of serious illness or death than adults, Covid-1 has killed more than 180 Americans. The American Academy of Pediatrics says about 2.2 million children have been infected with the coronavirus, up from 1.1 million in the last six weeks.
Moderena is also studying her Covid-1sh shots among elementary school-age youth. Pfizer and Modern are teaching 6-month-olds, even young children. Results are expected by the end of the year.
Read More Educational News
Keep Reading Latest Breaking News